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sites performed in 31%, and additional thrombolytic agents given in 23% of cases. PCI 
was angiographically successful in 86%, but the in-hospital mortality was 28%. The post- 
PCI length of stay was 7.0±9.7 days. Additionally, 1.7% had a CVA, 6.2% had renal fail- 
ure (RF), and 5.4% had vascular complications. Age was the single most predictive vari- 
able: mortality was 11.2% for ages up to 50; 20.0% for ages 51-60; 27.2% for ages 61- 
70; 34.8% for ages 71-80; 43.3% for ages above 80. Stenosis morphology (as A, B1, B 2 
or C) was not predictive. Logistic regression identified six muttivadate predictors of death: 
age (p<O.OOOl, odds ratio 1.45 (1.32, 1.60) for each 10 year increment); LVEF 
(p=O.0001, 0.76 (0.70, 0.62) for each 10% decrement); diabetes (p==O.O001, .65 (1.28, 
2.12)); RF(p=O.0005, 1.98 (1.35, 2.90)); pdor PCl (p=O.Ol, 0.69 (0.51, 0.93)); and urgent 
or emergent PC/(p<0.0001,0.32 (0.20, 0.53) and 2.54 (1.84, 3.51)). The model showed 
good discrimination with a ROC of 0.776, validated 0.736. Calibration was excellent, per- 
mitting development of a nomogram to estimate risk to over 60%. 
Conclusion: Thus, mortality after PCI for CSHOCK depends pdmarily on several histori- 
cal and clinical variables known to the physician at the time of decision for PCL Patients 
may be individually stratified as to risk of death. 
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Lloyd W. Klein, Michael A. Kutcher. Peter Block, Ronald Krone, William S. Weintraub, 
Richard E. Shaw, for the ACC-NCDR Registry, Rush-Presbyterian-St. Luke's Medical 
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Background: The increased use of coronary stents and glycopretein IIb/Ina inhibitors over 
the past five years has resulted in a marked decrease in the need for emergency coronary 
artery bypass surgery (am CABG) after failed PCI. However, situations still occur that 
require the availability of surgical options. 
Methods: To characterize clinical and angiographic findings predisposing to em CABG in 
contemporary practice, the 100,263 consecutive PCI procedures performed from 1998- 
2000 at 145 institutions contained in the ACC-NCDR database were analyzed. 
ResultS: 371 (0.4%) of PCI procedures required am CABG. The average age was 63+12 
years, 64% were men, 7.0% had pdor CABG, and 27.8% prior PCI. Stents were placed in 
29.1% (vs. 71% in the total registry), lib/Ilia agents used in 41.2% and thromboiytics in 
11.0%. LV ejection fraction was 52:~12%. The indications for PCI included MI <6 hours 
duration in 16.4%, cardiogenic shock in 6.7%, and unstable angina in 62.8%. Interestingly, 
50.9% were considered elective PCI, while 24.0% were urgent and 25.1% emergent. 
Stanosis morphology assessed by AHNACC class showed 2.2% A, 28.9% B 1 , 32.9% B 2, 
and 36.1% C type lesions. When evaluated by SCAI class, 49.3% were non-C patent, 
23.5% were C patent, 14.6% nomC occluded, and 12.7% C occluded. Tamponade 
ocourredin 9.4%. In-hospital mortality was 11.1% and Q wave MI developed in 6.5%. Mul- 
tivadate predictors of in-hospital mortality after em CABG are shock (odds ratio 3.30, 95% 
CI 1.0-10.9, p=0.05), peripheral vaecu/ar disease (3.20, 1.2-8.5, p=0.02),/eft main disease 
(3.33, 1.1-10.2, p=0.03), and emergent indication (2.70, 1.02-7.12, p=0.05). 
Conclusion: The need for am CABG in contemporary PCI is very low, but when required it 
cardes sedous mortality and morbidity implications. A disturbing percentage of cases 
requidng em CABG consist of what are usually thought of as "low-dsk" elective procedures 
with non-complex stenosis morphologies and/or totally occluded vessels. Tamponade or 
the inability to deliver a stent may influence the decision process. Thus, there is still a role 
for surgical standby and em CABG options in contemporary practice. 
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Background: Based on evidence from large clinical trials of subjects with and without 
coronary heart disease (CHD) or myocardial infarction (MI), statins are now well-estab- 
lished as the primary and secondary prevention of fatal and non-fatal coronary events; 
however, no study has prospectively evaluated the long-term effect of statins on clinical 
outcomes in patients who have undergone PCI. 
Methods: LIPS is a double-blind, randomized thai designed to compare the effect of flu- 
vastatin (40 mg bid) on major adverse cardiac event, ie MACE (cardiac death, non-fatal 
MI, repeat-CABG-or PCI)-free survival time in 1677 patients with CHD and successful 
TCT over a 3 year follow-up. Secondary endpoints are the incidence of MACE, non-car- 
diac deaths, hospitalization for other atherosclerotic diseases, changes in serum lipid 
concentrations, and anginal status. Inclusion cdtsria were: ages 18-80 years; first suc- 
cessful TCT within 6 months before randomization; total cholesterol of 135 - 270 mg/dL 
(3.5 - 7.0 mmol/L) with fasting triglycerides <400 mg/dL (<4.5 mmol/L) in the absence of 
any lipid-lowering therapy for at least 6 weeks. Baseline characteristics were as follows: 
Mean age (y) 60.5~_10 Anginal status (%) 
Male (%) 84.0 Unstable 49.7 
Smoking (%) 26.6 Stable 40.5 
Body Mass Index (kg/m 2) 26.6±3.3 Silent ischemia 9.8 
Blood pressure (mm Hg) 128.0/75.0 Previous MI 44.3 
Heart rate (bpm) 66.0+~11 Q-wave 26.8 
Diabetes mellitus (%) 12.0 Non Q-wave 17.6 
Totsl Number Of Lesions Treated 2222.0 
Summary: LIPS is the first study to investigate the effects of ststin therapy on MACE in 
patients who have undergone successful primary TCT for CHD. Final results will be pre- 
sented. 
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1125-9 Two-Year Outcomes Following Percutsneous 
Intervention: Beaumont Angiotsnsin Converting 
Enzyme Genotype and Endpoints Trial (The BAGET 
Trial) 
Kimbedv A. Skeldino. Laxmi Mehta, Demetris Demetriou, Domnita Cdsen, Judith A. 
Boura, Cindy L. Grines, William W. O'Neill, William Beaumont Hospital, Royal Oak, 
Michigan. 
Background: The angiotensin converting enzyme (ACE) genotype has been correlated 
with adverse cardiovascular events. This study was designed to determine if the ACE 
genotype was predictive of target vessel revascularization (TVR), myocardial infarction 
(MI), and mortality following percutaneous intervention. 
Methods: We prospectively analyzed the ACE genotype (D/D, D/I, I/I) in 756 patients 
undergoing percutaneous intervention to determine clinical restenosis and mortality at 
two year follow up. We analyzed baseline clinical parameters, angiographic details end 
outcomes in patients with D/D (255 patients) vs D/I (344 patients) vs I/I (154 patients). 
Results: Thus far in the D/D vs D/I vs I/I groups there is no difference in history of hyper- 
tension (76% vs 77% vs 71%, p=NS), hypedipidemia (76% vs 74% vs 83%, p=NS) or 
smoking (69% vs 74% vs 70%, p=NS). No difference in age (65+11, 65+11, 63+12, 
p=NS) or female gender (27% vs 24% vs 26%, p=NS) is seen. No difference in use of 
ACE inhibitors (46% vs 49% vs 42%, p=NS) or angiotensin receptor blockers (8% vs 
11% vs 14%, p=0.NS) is seen between the groups. History of diabetes mellitus (34% vs 
32% vs 33%, p=NS), coronary artery disease (85% vs 81% vs 84%, p=NS) and MI (53% 
vs 51% vs 54%, p=NS) are net different between groups. TVR is not affected by geno- 
type (23% vs 21% vs 15%, p=NS). The combined endpoint of TVR, MI and death did not 
differ by genotype as well (27% vs 26% vs 24%, p=NS). 
Conclusions: These findings sugggest that the ACE genotype does not correlate with 
TVR, MI or death at 2 years following percutaneous intervention. Therefore ACE geno- 
typing is not a useful test for risk stratification at the time of percutaneous intervention. 
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Vaccarino, Emory University School of Medicine, Atlanta, Georgia. 
Background. Younger women hospitalized for myocardial infarction are a high-risk 
group compared to men, with higher short and long-term mortality. This gender difference 
is less pronounced at older ages. We sought to determine whether younger women are 
also at increased risk of in-hospital mortality after PTCA compared to men, and whether 
this gender difference becomes less pronounced with advancing age. 
Methods. We studied 150,919 patients included in the National Cardiovascular Network 
(NCN) database who received PTCA at 23 clinical centers between October, 1993, and 
June, 2000, and for whom outcome information was available. 
Results. In logistic regression models that adjusted for demographics, medical history, 
prior PTCA, prior CABG, height, weight, renal insufficiency, LVEF, number of diseased 
vessels and elective admission, women had a higher odds of death compared to men. 
This greater risk was most pronounced in the youngest age group. Among patients < 50 
years old, the odds of death was 2 times higher in women compared to men. However, 
this gender difference was less substantial in older age groups. 
Conclusion. Younger women undergoing PTCA are at a substantially higher risk of in- 
hospital mortality compared to younger men, even after adjustment for traditional risk 
factors. At older ages, women are at only slightly higher risk of mortality compared to 
men. The reasons for the higher post-PTCA mortality risk in young women compared to 
young men need investigation. 
In-Hospital Mortality After PTCA, According to Gender and Age 
Women Men 
Age N Mortality N Mortality Adjusted OR 95% CI 
Group Rate (%) Rate (%) (Women Vs. Men) 
<50 4776 0.8 17171 0.4 2.1 1.2-3.7 
50-59 8896 0.8 27210 0.6 1.4 0.9-2.0 
60-69 14374 1.2 29458 0.8 1.4 1.1-1.9 
70-79 16170 2.5 22451 1.8 1.2 0.9-1,5 
80+ 5453 4.2 4870 3.5 1.4 1.0-1,9 
